Diabetes is life long affliction that causes a person’s blood sugar level to become too high. With the two main types of diabetes, type 2 is far more common. Around 90% of all adults with diabetes have type 2.
Types
Type 2 is where the body is not creating enough insulin or the body is not reacting correctly to the insulin. This type usually requires the managing of medication, finding the right medication for each person can take time. Also many of the medications have side affects.
Type 1 is when the level of glucose in blood to be too high. This happens when the body isn’t producing enough of the hormone insulin which controls the levels of glucose in blood.
Both types are manageable with the correct advice and medication.
There are articles below that explore the condition in many different ways. Covering new research and evidence.
University of Bristol researchers have discovered a VEGF-C gene therapy that protects the kidneys and may prevent serious complications in people with type 1 diabetes.
Emily Y. Chew, M.D., Director of the Division of Epidemiology and Clinical Applications and the Deputy Clinical Director at the National Eye Institute, part of the National Institutes of Health, examines why early detection is crucial to prevent blindness from diabetic retinopathy.
Lalit Singh Pukhrambam, PhD, and Ahmed S Ibrahim, PhD from Wayne State University School of Medicine in the U.S. focus here on the importance of combating diabetic retinopathy.
The Global Food Research Program, University of North Carolina in the U.S. share their perspective on how taxes on sugary beverages are important components of noncommunicable disease and obesity prevention strategies.
Here, OilsBySimpson Founder Kevin Simpson and Clinical Professor, Consultant Physician and Research Director, Filip Krag Knop, explain what we know so far about CBD’s effect on Type 2 diabetes and why running a clinical trial is so important.
Here, we find out about the role that the National Institute of Environmental Health Sciences, a publicly-funded institute, when it comes to funding obesity research in the U.S. today.
Dr Elizabeth Robertson, Director of Research at Diabetes UK explains why 2019 marked turning a corner in the prevention of Type 1 diabetes but adds that there is still more research to be done in this area.
John Greenwood PhD FRCPath and Stephen E. Moss PhD from UCL Institute of Ophthalmology discuss the vasculature in health and disease, a major focus of their research.
Digitally enabled pathway personalisation is leveraging actionable data insights and dynamic intelligence to drive better outcomes as part of the Prevention 3.0 agenda
Lalit P. Singh, Associate Professor at Wayne State University School of Medicine, explains the role of TXNIP in mitochondrial-lysosomal axis dysregulation in diabetic retinopathy.
In this interview, Jean-Marie Dangou from the WHO Regional Office for Africa discusses diabetes in the African region, including lack of access to treatment and ongoing action to solve this.
